DK1949903T3 - Selektive A2A-receptor-antagonister til behandling af atrieflimmer - Google Patents
Selektive A2A-receptor-antagonister til behandling af atrieflimmerInfo
- Publication number
- DK1949903T3 DK1949903T3 DK06830873.3T DK06830873T DK1949903T3 DK 1949903 T3 DK1949903 T3 DK 1949903T3 DK 06830873 T DK06830873 T DK 06830873T DK 1949903 T3 DK1949903 T3 DK 1949903T3
- Authority
- DK
- Denmark
- Prior art keywords
- atrial fibrillation
- receptor antagonists
- selective
- treatment
- antagonists
- Prior art date
Links
- 206010003658 Atrial Fibrillation Diseases 0.000 title abstract 4
- 101150051188 Adora2a gene Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 2
- 102000007471 Adenosine A2A receptor Human genes 0.000 abstract 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 abstract 1
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 abstract 1
- 230000001746 atrial effect Effects 0.000 abstract 1
- 210000004413 cardiac myocyte Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200502545A ES2273599B1 (es) | 2005-10-14 | 2005-10-14 | Compuestos para el tratamiento de la fibrilacion auricular. |
| PCT/ES2006/000564 WO2007045705A2 (es) | 2005-10-14 | 2006-10-10 | Compuestos para el tratamiento de la fibrilación auricular |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1949903T3 true DK1949903T3 (da) | 2012-07-30 |
Family
ID=37962872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06830873.3T DK1949903T3 (da) | 2005-10-14 | 2006-10-10 | Selektive A2A-receptor-antagonister til behandling af atrieflimmer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8012973B2 (enExample) |
| EP (1) | EP1949903B8 (enExample) |
| JP (1) | JP2009511551A (enExample) |
| CN (1) | CN101325956B (enExample) |
| AT (1) | ATE553763T1 (enExample) |
| AU (1) | AU2006303240B2 (enExample) |
| BR (1) | BRPI0617369A2 (enExample) |
| CA (1) | CA2626020A1 (enExample) |
| DK (1) | DK1949903T3 (enExample) |
| ES (2) | ES2273599B1 (enExample) |
| MX (1) | MX2008004886A (enExample) |
| RU (1) | RU2445099C2 (enExample) |
| WO (1) | WO2007045705A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105785053B (zh) * | 2011-10-17 | 2018-09-21 | 霍夫曼-拉罗奇有限公司 | 风险患者和中风原因的基于肌钙蛋白和bnp的诊断 |
| CZ2014307A3 (cs) * | 2014-05-06 | 2016-01-13 | Vysoká škola chemicko- technologická v Praze | Kofein-8-hydrazony jako nová cytostatika pro léčbu onkologických onemocnění |
| WO2017008205A1 (en) * | 2015-07-10 | 2017-01-19 | Merck Sharp & Dohme Corp. | Substituted aminoquinazoline compounds as a2a antagonist |
| CN108570054B (zh) * | 2017-03-07 | 2021-07-16 | 广州再极医药科技有限公司 | 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用 |
| CN112533923B (zh) | 2018-06-04 | 2024-07-09 | 爱克思科技有限公司 | 作为腺苷受体拮抗剂的吡唑并嘧啶化合物 |
| CN108864114B (zh) | 2018-06-04 | 2020-11-06 | 应世生物科技(南京)有限公司 | 选择性a2a受体拮抗剂 |
| US20230218716A1 (en) * | 2020-05-06 | 2023-07-13 | Ohio State Innovation Foudation | Compositions and methods for treating atrial fibrillation |
| KR102675647B1 (ko) * | 2021-06-30 | 2024-06-18 | 단국대학교 천안캠퍼스 산학협력단 | 인간치아줄기세포의 상아모세포로의 분화를 위한 신규 화합물 및 이의 의학적 용도 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US599387A (en) * | 1898-02-22 | Cabinet | ||
| US4772607A (en) * | 1986-05-20 | 1988-09-20 | Warner-Lambert Company | Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
| US4780464A (en) * | 1986-12-08 | 1988-10-25 | Warner-Lambert Company | (1,2,4)triazolo(4,3-a)quinoxaline-4-amines |
| CA2094270C (en) | 1990-10-18 | 1997-01-21 | Fumio Suzuki | Xanthine derivatives |
| GB9124968D0 (en) * | 1991-11-25 | 1992-01-22 | Ici Plc | Chemical process |
| US5484920A (en) | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
| US5543415A (en) | 1992-07-08 | 1996-08-06 | Kyowa Hakko Kogyo Co., Ltd. | Antidepressants |
| IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| AU7237294A (en) | 1993-07-27 | 1995-02-28 | Kyowa Hakko Kogyo Co. Ltd. | Remedy for parkinson's disease |
| US5736528A (en) * | 1993-10-28 | 1998-04-07 | University Of Florida Research Foundation, Inc. | N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists |
| ATE218139T1 (de) | 1994-02-23 | 2002-06-15 | Kyowa Hakko Kogyo Kk | Xanthin-derivate |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| US6051578A (en) * | 1996-02-12 | 2000-04-18 | Pfizer Inc. | Pyrazolopyrimidines for treatment of CNS disorders |
| US6060478A (en) * | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| JP4195729B2 (ja) | 1997-03-24 | 2008-12-10 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体 |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| EP1016407B1 (en) | 1997-09-05 | 2006-05-10 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives for treating brain ischemia |
| US6197788B1 (en) | 1997-11-26 | 2001-03-06 | Vernalis Research Limited | (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders |
| CA2315736A1 (en) | 1998-01-05 | 1999-07-15 | Eisai Co., Ltd. | Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus |
| AU2639299A (en) | 1998-02-24 | 1999-09-15 | Kyowa Hakko Kogyo Co. Ltd. | Remedies/preventives for parkinson's disease |
| DE19930558A1 (de) | 1998-07-24 | 2000-01-27 | Marquardt Gmbh | Elektrischer Schalter |
| EP1109801A1 (en) * | 1998-09-04 | 2001-06-27 | The Procter & Gamble Company | Substituted dihydrobenzopyrans useful as antiarrhythmic agents |
| GB9819384D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
| AU4431000A (en) | 1999-05-12 | 2000-12-05 | Fujisawa Pharmaceutical Co., Ltd. | Novel use |
| US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
| GB9915437D0 (en) | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| WO2001002400A1 (en) | 1999-07-02 | 2001-01-11 | Eisai Co., Ltd. | Fused imidazole compounds and remedies for diabetes mellitus |
| JP3347691B2 (ja) * | 1999-07-05 | 2002-11-20 | プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド | 抗不整脈及び抗細動剤として有用な新規４−オキソ環式尿素類 |
| BR0013673A (pt) | 1999-08-31 | 2002-05-28 | Univ Vanderbilt | Antagonistas seletivos de receptores de adenosina a2b |
| US6355653B1 (en) | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| DE19947154A1 (de) | 1999-10-01 | 2001-10-04 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| US6194366B1 (en) | 1999-11-16 | 2001-02-27 | Esc, Inc. | Post chemical-mechanical planarization (CMP) cleaning composition |
| AUPQ441499A0 (en) | 1999-12-02 | 2000-01-06 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound |
| US6258793B1 (en) * | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
| MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| CA2398274C (en) | 2000-02-25 | 2009-09-22 | F. Hoffmann-La Roche Ag | Adenosine receptor modulators |
| EP1510222A3 (en) | 2000-04-26 | 2007-05-23 | Eisai R&D Management Co., Ltd. | Medicinal compositions promoting bowel movement |
| MXPA02011625A (es) | 2000-05-26 | 2003-03-27 | Schering Corp | Antagonistas receptores de adenosina a2a. |
| KR100526487B1 (ko) | 2000-06-21 | 2005-11-08 | 에프. 호프만-라 로슈 아게 | 벤조티아졸 유도체 |
| MXPA03001136A (es) | 2000-08-11 | 2003-06-24 | Eisai Co Ltd | Compuesto de 2-aminopiridina y uso medico del mismo. |
| GB0100620D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
| AR037243A1 (es) | 2001-10-15 | 2004-11-03 | Schering Corp | Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
| US6599901B1 (en) * | 2001-11-19 | 2003-07-29 | Hoffman-La Roche Inc. | Pyridone substituted benzothiazole derivatives |
| AU2002352933A1 (en) | 2001-11-30 | 2003-06-17 | Schering Corporation | [1,2,4]-triazole bicylic adenosine A2a receptor antagonists |
| TW200300686A (en) | 2001-11-30 | 2003-06-16 | Schering Corp | Adenosine A2a receptor antagonists |
| ATE453647T1 (de) | 2001-11-30 | 2010-01-15 | Schering Corp | Adenosin a2a rezeptor antagonisten |
| ES2279903T3 (es) | 2001-12-18 | 2007-09-01 | Cv Therapeutics, Inc. | Antagonistas del receptor a2a de adenosina. |
| WO2003057689A1 (en) | 2002-01-02 | 2003-07-17 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
| ES2208063B1 (es) | 2002-04-01 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida. |
| AU2002950853A0 (en) | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
| JP4498140B2 (ja) | 2002-08-30 | 2010-07-07 | 協和発酵キリン株式会社 | 行動障害治療剤 |
| CA2500228A1 (en) | 2002-09-24 | 2004-04-08 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]-triazolo[1,5-c]pyrimidine derivative |
| NZ540493A (en) | 2002-12-19 | 2008-04-30 | Schering Corp | Uses of adenosine A2a receptor antagonists |
| WO2004085439A1 (en) * | 2003-03-27 | 2004-10-07 | Pfizer Products Inc. | Substituted 4-amino[1,2,4]triazolo[4,3-a]quinoxalines |
| US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| EP1622912B1 (en) | 2003-04-23 | 2009-05-27 | Schering Corporation | 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists |
| EA200600688A1 (ru) | 2003-10-03 | 2006-10-27 | Орто-Макнейл Фармасьютикал, Инк. | Арилинденпиридины и арилинденпиримидины и их применение в качестве антагонистов аденозинового рецептора а2а |
| TW200524887A (en) | 2003-10-27 | 2005-08-01 | Lundbeck & Co As H | N-thiazol-2-yl-benzamide derivatives |
| EP1678160A1 (en) | 2003-10-27 | 2006-07-12 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| CA2547248A1 (en) | 2003-12-01 | 2005-06-16 | Schering Corporation | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines |
| WO2005058883A1 (en) | 2003-12-15 | 2005-06-30 | Almirall Prodesfarma Ag | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
-
2005
- 2005-10-14 ES ES200502545A patent/ES2273599B1/es not_active Expired - Fee Related
-
2006
- 2006-10-10 AT AT06830873T patent/ATE553763T1/de active
- 2006-10-10 AU AU2006303240A patent/AU2006303240B2/en not_active Ceased
- 2006-10-10 EP EP06830873A patent/EP1949903B8/en not_active Not-in-force
- 2006-10-10 DK DK06830873.3T patent/DK1949903T3/da active
- 2006-10-10 WO PCT/ES2006/000564 patent/WO2007045705A2/es not_active Ceased
- 2006-10-10 CA CA002626020A patent/CA2626020A1/en not_active Abandoned
- 2006-10-10 US US12/090,115 patent/US8012973B2/en not_active Expired - Fee Related
- 2006-10-10 MX MX2008004886A patent/MX2008004886A/es active IP Right Grant
- 2006-10-10 JP JP2008535047A patent/JP2009511551A/ja active Pending
- 2006-10-10 BR BRPI0617369-1A patent/BRPI0617369A2/pt not_active IP Right Cessation
- 2006-10-10 CN CN200680046601XA patent/CN101325956B/zh not_active Expired - Fee Related
- 2006-10-10 ES ES06830873T patent/ES2386377T3/es active Active
- 2006-10-10 RU RU2008118995/15A patent/RU2445099C2/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101325956A (zh) | 2008-12-17 |
| ES2273599B1 (es) | 2008-06-01 |
| JP2009511551A (ja) | 2009-03-19 |
| ATE553763T1 (de) | 2012-05-15 |
| RU2445099C2 (ru) | 2012-03-20 |
| WO2007045705A2 (es) | 2007-04-26 |
| ES2273599A1 (es) | 2007-05-01 |
| WO2007045705A3 (es) | 2007-06-14 |
| CN101325956B (zh) | 2012-02-29 |
| BRPI0617369A2 (pt) | 2011-07-26 |
| EP1949903B1 (en) | 2012-04-18 |
| MX2008004886A (es) | 2009-03-02 |
| CA2626020A1 (en) | 2007-04-26 |
| AU2006303240B2 (en) | 2012-07-12 |
| ES2386377T3 (es) | 2012-08-20 |
| US8012973B2 (en) | 2011-09-06 |
| RU2008118995A (ru) | 2009-11-20 |
| EP1949903B8 (en) | 2012-05-23 |
| US20090312332A1 (en) | 2009-12-17 |
| AU2006303240A1 (en) | 2007-04-26 |
| EP1949903A2 (en) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20080278L (no) | Prodrugs av A2B-adenosinreseptorantagonister | |
| BRPI0912411A2 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro. | |
| EP1850658A4 (en) | IMPROVED PROCESS FOR THE TREATMENT OF DEGENERATIVE DISEASES OF RETINA | |
| DE602005020127D1 (de) | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors | |
| CY1117693T1 (el) | ΚΡΥΣΤΑΛΛΙΚΑ ΑΛΑΤΑ ΤΟΥ ΑΝΑΣΤΟΛΕΑ ΚΙΝΑΣΗΣ JANUS (R)-3-(4-(7H-ΠΥΡΡΟΛΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-4-ΥΛΟ)-1Η-ΠΥΡΑΖΟΛ-1-ΥΛΟ)-3-ΚΥΚΛΟΠΕΝΤΥΛΟ-ΠΡΟΠΑΝΟΝΙΤΡΙΛΙΟΥ | |
| PL2081435T3 (pl) | Inhibitory kinazy tyrozynowej brutona | |
| CL2007002708A1 (es) | Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros. | |
| IL189499A (en) | Use of 2,4-diaminopyrimidines or 4-aminopyrimidines for the preparation of a medicament for the treatment of a respiratory disease mediated by a p2x3 or p2x2/3 receptor antagonist | |
| WO2007022257A3 (en) | Monocyclic and bicyclic compounds and methods of use | |
| ATE453642T1 (de) | Substituierte phenylaminopyrimidine | |
| WO2008043052A3 (en) | Human antibodies neutralizing human metapneumovirus | |
| NL1028087A1 (nl) | Sulfonamiderivaten voor de behandeling van ziekten. | |
| ECSP055669A (es) | Derivados de pirimidinona como agentes terapéuticos contra procesos de remodelación, isquemicos e inflamatorios agudos y cronicos | |
| CY1117174T1 (el) | ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ | |
| NO20074780L (no) | Heterocyklylamidsubstituerte imidazoler | |
| DK1778239T3 (da) | Adenosin-a3-receptor-agonister til behandling af sygdomme forbundet medtørre øjne, herunder sjögrens syndrom | |
| DK1949903T3 (da) | Selektive A2A-receptor-antagonister til behandling af atrieflimmer | |
| ZA200802552B (en) | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | |
| CY1112568T1 (el) | Χρηση των πυριμιδυλαμινοβενζαμιδων για τη θεραπεια των νοσων που ανταποκρινονται στην ρυθμιση της δρασης της τιε-2 κινασης | |
| UY31717A1 (es) | (pirazolilcarbonil) imidazolidinonas sustituidas y su uso | |
| ZA200803236B (en) | Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders | |
| CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας | |
| DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
| CL2004000677A1 (es) | Compuestos derivados de piperidinas; procedimiento de preparacion; composicion farmaceutica; utiles como moduladores de la actividad del receptor de quimioquina en el tratamiento de enfermedades autoinmunes, inflamatorias, proliferativas o mediadas i | |
| BRPI0612624A2 (pt) | métodos para tratar doença vascular em um humano, e para prevenção e/ou tratamento de uma doença induzida por trombose ou uma doença induzida por tromboembolismo em um humano, e, uso de um composto |